Table 2.
Clinical and virological characteristics of the 10 patients studied before and during treatment mean ± SD
| Patient and time of treatment | Sex | Age | Viral load log IU/mL | n | NT substitutions/master sequence | AA substitutions/master sequence | Genetic distance |
| SVR1-D0 | F | 48 | 2.00 | 15 | 4.5 ± 2.3 | 2.5 ± 1.4 | 0.0065 ± 0.0008 |
| SVR2-D0 | F | 53 | 4.55 | 13 | 5.1 ± 3.6 | 3.3 ± 2.1 | 0.0070 ± 0.0011 |
| SVR3-D0 | M | 43 | 4.71 | 8 | 10.3 ± 3.6 | 4.7 ± 1.9 | 0.0105 ± 0.0018 |
| SVR4-D0 | M | 59 | 6.24 | 16 | 15.4 ± 8.0 | 7.5 ± 4.9 | 0.0172 ± 0.0022 |
| SVR4-M3 | - | - | 1.61 | 13 | 3.6 ± 2.1 | 1.8 ± 1.0 | 0.0051 ± 0.0008 |
| SVR5-D0 | F | 65 | 5.44 | 15 | 10.1 ± 6.6 | 4.9 ± 2.0 | 0.0171 ± 0.0016 |
| SVR5-M3 | - | - | 2.77 | 17 | 6.4 ± 2.4 | 3.3 ± 1.6 | 0.0070 ± 0.0010 |
| SVR6-D0 | M | 47 | 7.26 | 17 | 15.9 ± 10.5 | 8.5 ± 5.1 | 0.0192 ± 0.0022 |
| SVR6-M3 | - | - | 2.18 | 6 | 4.0 ± 1.7 | 2.4 ± 1.3 | 0.0062 ± 0.0012 |
| SVR7-D0 | F | 51 | 6.61 | 15 | 29.3 ± 8.5 | 7.3 ± 2.7 | 0.0294 ± 0.0029 |
| SVR7-M3 | - | - | 5.42 | 15 | 12.6 ± 4.2 | 4.6 ± 2.2 | 0.0156 ± 0.0016 |
| NR1-D0 | M | 35 | 5.13 | 17 | 15.2 ± 4.3 | 3.5 ± 1.9 | 0.0181 ± 0.0020 |
| NR1-M3 | - | - | 5.24 | 9 | 15.3 ± 4.4 | 4.8 ± 1.7 | 0.0143 ± 0.0020 |
| NR1-M6 | - | - | 2.83 | 4 | 4.5 ± 3.1 | 2.0 ± 3.4 | 0.0041 ± 0.0013 |
| NR2-D0 | F | 50 | 5.90 | 17 | 15.6 ± 6.4 | 5.2 ± 2.9 | 0.0181 ± 0.0020 |
| NR2-M3 | - | - | 5.87 | 12 | 9.5 ± 3.6 | 3.9 ± 1.8 | 0.0125 ± 0.0013 |
| NR2-M6 | - | - | 5.77 | 10 | 10.3 ± 3.3 | 4.0 ± 2.2 | 0.0274 ± 0.0020 |
| NR3-D0 | F | 44 | 5.63 | 14 | 10.9 ± 3.7 | 4.4 ± 2.2 | 0.0279 ± 0.0021 |
| NR3-M3 | - | - | 5.79 | 11 | 11.1 ± 2.7 | 4.0 ± 2.8 | 0.0157 ± 0.0017 |
| NR3-M6 | - | - | 5.00 | 12 | 10.8 ± 3.3 | 4.4 ± 2.0 | 0.0154 ± 0.0015 |
F: Female; M: Male; n: number of PCR products analyzed; D0: beginning of the treatment; M3: 3 mo of treatment; SVR: Sustained Virological Responders; NR: Non-Responders to IFN-ribavirin therapy.